ICP-B794 / InnoCare - LARVOL DELTA

Continued Breakthroughs Across Multiple Pipelines (The Manila Times) - "...mesutoclax’s latest data will be presented at the 2026 American Society of Clinical Oncology (ASCO) annual meeting...The novel B7-H3 targeted ADC ICP-B794 showed promising preclinical data and was selected for presentation at the 2026 American Association for Cancer Research (AACR) annual meeting. The Phase I ascending dose trial is progressing....The IND application for the novel CDH17-targeted ADC ICP-B208 has been submitted which will be developed for the treatment of gastrointestinal cancers, including gastric, colorectal, pancreatic ductal adenocarcinoma, and cholangiocarcinoma."

IND • P1 data • Preclinical • Acute Myelogenous Leukemia • Cholangiocarcinoma • Colorectal Cancer • Gastric Cancer • Myelodysplastic Syndrome • Pancreatic Ductal Adenocarcinoma

ICP-B794, a B7H3-targeting ADC with a novel linker-payload, demonstrated superior anti-tumor activity and large therapeutic window in preclinical studies (AACR 2026) - P1 | "In summary, ICP-B794 created based on a novel ADC platform exhibited a favorable preclinical profile, including high potency in the in vitro assays, efficacious at very dose level in the in vivo xenograft models, overcoming resistance to DS-7300 and a larger safety window. ICP-B794 is currently being evaluated in a Phase I first-in-human clinical trial (NCT07136558)."

ADC • First-in-human • Late-breaking abstract • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD276

Preclinical Data of Novel B7-H3 ADC ICP-B794 Unveiled at 2026 AACR, Demonstrating Superior Anti-Tumor Activity and Safety (GlobeNewswire) - "ICP-B794 exhibited excellent drug-to-antibody ratio (DAR) value stability and low payload release in human plasma. In the in vitro cellular assays, ICP-B794 demonstrated significantly improved cell killing activity compared to similar drugs. It also demonstrated superior in vivo efficacy to B7H3-ADCs generated from other platforms, achieving therapeutic outcomes even at low dose."

Preclinical • Solid Tumor

InnoCare Pharma's novel ADC drug ICP-B794 has been successfully administered to its first patient [Google translation] (InnoCare Pharma Press Release)

Trial status • Solid Tumor

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Not yet recruiting | Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

New P1 trial • Solid Tumor

InnoCare Announces Approval of Clinical Trial of a Novel ADC ICP-B794 in China (Businesswire) - "InnoCare Pharma...announced today the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct the clinical trial of a novel B7-H3 targeted ADC ICP-B794....ICP-B794 is a novel ADC comprising a humanized anti-B7-H3 monoclonal antibody conjugated to potent in-house developed payload via a protease-cleavable linker. This combination ensures precise targeting of tumor cells while minimizing off-target effects, offering a promising treatment for solid tumors such as lung cancer, esophageal cancer, nasopharyngeal cancer, head and neck squamous cell carcinomas, prostate cancer, and others."

New trial • Esophageal Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Prostate Cancer • Squamous Cell Carcinoma of Head and Neck